VisionPhase 4NCT01057966
Bioavailability of Nutrients Contained in Softgel Capsules vs Tablets
A Phase 4 study testing ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength), ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength) and ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength) in people with Vision, run by Alcon Research at 1 site in United States.
Trial summary
This study is a comparison of the bioavailability of nutrients contained in softgel capsules vs tablets. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Vision
- What is being tested?
- ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength), ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength) and ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteUnited States
- Study dates
- Feb 2010to Sep 2011
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 18 to 35
- Body Mass Index (BMI) 21-27 kg/m2
- Must be able to give written informed consent
- Subjects must be willing to comply with all study requirements.
- Subjects must understand, sign and be given a copy of the written Informed Consent form.
Who cannot join
- Subjects for whom both eyes do not meet all inclusion criteria and either eye meets exclusion criteria
- Subjects who are pregnant, lactating or planning to be pregnant during the course of the study
- Subjects with known sensitivity to planned study concomitant medications
- Subjects participating in any other ophthalmic drug or device clinical trial within 30 days of this clinical investigation.
- Use of ocular drugs, other than study medications, during the study and within 14 days prior to study entry or any other ocular medication
Trial locations and contacts
1 site in 1 country.
United States1 site
Contact Alcon Call Center For Trial Locations
Fort Worth, Texas, 76134
About this study
This study is a comparison of the bioavailability of nutrients contained in softgel capsules vs tablets.
- Conditions
- Vision
- Being tested
- ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength), ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength), ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)
- Keywords
- Bioavailability, Ocular Vitamins
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength)Dietary supplement
Single full strength dose capsule taken one time
ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength)Dietary supplement
Single half strength dose capsule taken one time
ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)Dietary supplement
Single, full strength dose tablet taken one time
| Study group | Role | What they receive |
|---|---|---|
| ICAPS AREDS Softgel Capsule - Full Strength | Experimental | ICAPS Eye Vitamin and Mineral Supplement - Softgel Receives: Dietary Supplement: ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength) |
| ICAPS AREDS Softgel Capsule - Half Strength | Experimental | ICAPS Eye Vitamin and Mineral Supplement - Softgel (half -strength) Receives: Dietary Supplement: ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength) |
| ICAPS AREDS coated tablets - Full Strength | Experimental | ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets Receives: Dietary Supplement: ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bioavailability of nutrients
Measured: 1 week for each treatment cross-over period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2010 (estimated)
- Study startFeb 2010
- Primary completionSep 2011
- Study completionSep 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for VisionStudies of the same condition, open and under way.
- More trials run by Alcon ResearchThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alcon Research
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01057966
- Sponsor's protocol ID
- SMA-09-32
- Status last verified
- Jan 2012
- First submitted
- 27 Jan 2010
- Last updated
- 2 Feb 2012
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Feb 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bioavailability of Nutrients Contained in Softgel Capsules vs Tablets
- ClinicalTrials.gov ID
- NCT01057966
- Acronym / sponsor ID
- SMA-09-32
- Conditions
- Vision
- Keywords
- Bioavailability, Ocular Vitamins
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Alcon ResearchIndustry (pharma, biotech, devices)
- Study start
- Feb 2010
- Primary completion
- Sep 2011 (actual)
- Study completion
- Sep 2011 (actual)
- First posted
- 28 Jan 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a comparison of the bioavailability of nutrients contained in softgel capsules vs tablets.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| ICAPS AREDS Softgel Capsule - Full Strength | Experimental | Dietary Supplement: ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength)ICAPS Eye Vitamin and Mineral Supplement - Softgel |
| ICAPS AREDS Softgel Capsule - Half Strength | Experimental | Dietary Supplement: ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength)ICAPS Eye Vitamin and Mineral Supplement - Softgel (half -strength) |
| ICAPS AREDS coated tablets - Full Strength | Experimental | Dietary Supplement: ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age 18 to 35
- Body Mass Index (BMI) 21-27 kg/m2
- Must be able to give written informed consent
- Subjects must be willing to comply with all study requirements.
- Subjects must understand, sign and be given a copy of the written Informed Consent form.
Key exclusion criteria (5 listed)
- Subjects for whom both eyes do not meet all inclusion criteria and either eye meets exclusion criteria
- Subjects who are pregnant, lactating or planning to be pregnant during the course of the study
- Subjects with known sensitivity to planned study concomitant medications
- Subjects participating in any other ophthalmic drug or device clinical trial within 30 days of this clinical investigation.
- Use of ocular drugs, other than study medications, during the study and within 14 days prior to study entry or any other ocular medication
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength)Single full strength dose capsule taken one time | Dietary supplement | ICAPS AREDS Softgel Capsule - Full Strength |
| ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength)Single half strength dose capsule taken one time | Dietary supplement | ICAPS AREDS Softgel Capsule - Half Strength |
| ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)Single, full strength dose tablet taken one time | Dietary supplement | ICAPS AREDS coated tablets - Full Strength |
Primary outcome
Bioavailability of nutrients
Time frame: 1 week for each treatment cross-over period
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Feb 2012.
Related trials for Vision
RecruitingObservational study
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis
RecruitingObservational study
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
Pleuropulmonary Blastoma, Cystic Nephroma
Enrolling by invitationPhase 2
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31
PSP - Progressive Supranuclear Palsy
RecruitingPhase 3
A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the Day
Insomia Disorder
RecruitingPhase 1/2
Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial
Parkinson Disease, Multiple System Atrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength), ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength) and ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength) in people with Vision, run by Alcon Research at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Feb 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bioavailability of nutrients (time frame: 1 week for each treatment cross-over period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2012.